SARS-CoV-2 Pathogenesis

SARS-CoV-2 发病机制

• 批准号: 10272267
• 负责人: Jeffery Taubenberger
• 金额: $ 156.87万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10272267
• 关键词: 2019-nCoV; Animals; Coronavirus; Gene Expression; Goals; Histopathology; Human; Immunologic Markers; Inactivated Vaccines; Infection; Inflammatory Response; Laboratory Animal Models; Lead; Molecular Analysis; Molecular Virology; Organ; Pathogenesis; Pulmonary Pathology; Research; Research Project Grants; Role; Systems Biology; Therapeutic; Thrombosis; Vaccine Antigen; Vaccines; Viral; Virus; Virus Diseases; human model; inflammatory marker; novel; novel vaccines; pandemic disease; particle; pre-clinical; preclinical study

In late 2019, a novel beta coronavirus emerged in humans to cause a global pandemic. The virus, SARS-CoV-2 has resulted in over 160,000 fatal cases in the U.S. in the first 6 months of 2020. Understanding how infection can lead to serious or fatal illness is critically important for efforts to develop therapeutics and vaccines. In this research project, a systems biology approach is being employed to investigate fatal cases of SARS-CoV-2, including histopathology, molecular analyses of host gene expression, molecular virology, and other inflammatory and immune markers. In parallel, two novel vaccines are being developed and evaluated in pre-clinical studies in experimental animals. One will use a viral like particle construct as the vaccine antigen and another will evaluate whole virus inactivated vaccines.

2019年底，人类出现了一种新颖的β冠状病毒，引起全球大流行。该病毒SARS-COV-2在2020年的前6个月在美国导致了16万例致命病例。了解感染如何导致严重或致命疾病对于开发治疗和疫苗的努力至关重要。 在该研究项目中，正在采用一种系统生物学方法来研究SARS-COV-2的致命病例，包括组织病理学，宿主基因表达的分子分析，分子病毒学以及其他炎症和免疫标记。 同时，在实验动物的临床前研究中正在开发和评估两种新型疫苗。一个人将使用病毒等颗粒构建体作为疫苗抗原，另一种将评估整个病毒灭活的疫苗。